@article{121006193a4141b39f1f051a52719f7b,
title = "Benefits of Metformin in Attenuating the Hallmarks of Aging",
abstract = "Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.",
keywords = "TAME, aging, aging hallmarks, health span, longevity, metabolism, metformin",
author = "Kulkarni, {Ameya S.} and Sriram Gubbi and Nir Barzilai",
note = "Funding Information: This work is supported by the grants from the National Institutes of Health ( P01AG021654 ) (N.B.), Nathan Shock Center of Excellence in the Basic Biology of Aging ( P30AG038072 ) (N.B.), and Paul F. Glenn Center for the Biology of Aging Research at the Albert Einstein College of Medicine (N.B.). A.S.K. is supported by the Albert Einstein College of Medicine {\textquoteright}s Ph.D. in Clinical Investigation program. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = jul,
day = "7",
doi = "10.1016/j.cmet.2020.04.001",
language = "English (US)",
volume = "32",
pages = "15--30",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "1",
}